Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
8,186,092
-
Share change
-
+3,718,770
-
Total reported value
-
$20,953,817
-
Put/Call ratio
-
24%
-
Price per share
-
$2.56
-
Number of holders
-
63
-
Value change
-
+$9,615,818
-
Number of buys
-
42
-
Number of sells
-
15
Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q1 2025
As of 31 Mar 2025,
Protalix BioTherapeutics, Inc. - COM (PLX) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,186,092 shares.
The largest 10 holders included
RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, NORTHERN TRUST CORP, MARSHALL WACE, LLP, Connor, Clark & Lunn Investment Management Ltd., Stratos Wealth Partners, LTD., JANE STREET GROUP, LLC, GOLDMAN SACHS GROUP INC, and BlackRock, Inc..
This page lists
63
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.